<DOC>
	<DOCNO>NCT01768273</DOCNO>
	<brief_summary>The purpose study determine safety tolerability PA-824 give single dose midazolam , determine whether PA-824 inhibits CYP3A clinically important degree measure effect PA-824 pharmacokinetics midazolam , know CYP3A substrate .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Interaction Between PA-824 Midazolam</brief_title>
	<detailed_description>This study open-label , fix sequence design . 14 subject receive single dose 2 mg midazolam , follow 2-day wash-out . Following wash-out , subject receive PA-824 daily 14 day . All patient receive single dose 2 mg midazolam 14th day PA-824 dosing . This study evaluate 400 mg PA-824 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Have ability understand requirement study , provide write informed consent ( evidenced signature inform consent document approve IRB ) , agree abide study restriction . 2 . Be healthy nontobacco/nicotine use ( 6month minimum ) adult subject , 19 50 year age , inclusive . 3 . Be medically healthy subject clinically insignificant Screening result ( among laboratory profile , medical history , ECGs , physical exam ) , deem Principal Investigator . 4 . Have body mass index 18 29 . 5 . Have negative urine test result alcohol drug abuse amphetamine , cannabinoids , cocaine metabolite Screening Checkin . 6 . Agree follow requirement set forth protocol regard pregnancy control donation sperm , blood , blood component . Medical History 1 . Any clinically significant ( deem Principal Investigator ) history , acute illness ( resolve within 4 week screen ) , presence cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal ( include eat disorder ) , endocrine , metabolic , immunologic , dermatologic , neurologic , psychological , psychiatric disease . 2 . History peptic ulcer disease , gastritis , esophagitis , gastroesophageal reflux disease . 3 . History clinically significant cardiac abnormality ( deem Principal Investigator ) . 4 . Any clinically significant ECG abnormality Screening ( deem Principal Investigator Sponsor 's Medical Monitor ) Note : following consider clinically significant without consult Sponsor 's Medical Monitor : Heart rate â‰¥50 beat per minute ( sinus bradycardia heart rate 45 49 , inclusive , acceptable young athletic subject ) Mild first degree AV block ( PR interval &lt; 0.23 sec ) Right leave axis deviation Incomplete right bundle branch block Isolated leave anterior fascicular block ( leave anterior hemiblock ) young athletic subject 5 . History prolong QT interval . 6 . Family history LongQT Syndrome sudden death without precede diagnosis condition could causative sudden death ( know coronary artery disease CHF terminal cancer ) 7 . Resting pulse rate &lt; 40 &gt; 100 bpm Screening . 8 . At Screening blood pressure great 140/90 mm Hg 95/65 mm Hg ( supine , minimum 5minute supine rest ) 9 . At either Screening predose read first dose , QTcB ( Bazett 's correction ) &gt; 450ms men woman , calculated average triplicate read collect screen predose sit . 10 . At either Screening predose read first dose , QTcF ( Fridericia 's correction ) &gt; 450ms men woman , calculated average triplicate read collect screen predose sit . 11 . History hypokalemia hypomagnesemia . 12 . History presence alcoholism drug abuse within past 2 year ( deem Principal Investigator ) . 13 . Use alcohol within 72 hour prior dose . 14 . Significant history drug and/or food allergy ( deem Principal Investigator ) . 15 . For woman , subject pregnant ( positive test serum HCG Screening Checkin ) , breastfeed plan conceive child within 30 day cessation treatment . 16 . For male , plan father child within 12 week cessation treatment . 17 . History lens opacity evidence lens opacity slit lamp ophthalmologic examination . Specific Treatments 18 . Any contraindication use nitroimidazoles , prior treatment PA824 OPC67683 . 19 . Use systemic topical prescription medication within 14 day prior dose study , except hormonal contraceptive woman . 20 . Use systemic overthecounter medication include vitamin , herbal preparation , antacid , cough cold remedy , etc. , within 7 day prior dose study treatment period . 21 . Use drug substance within 30 day prior dose , know strong inhibitor inducer cytochrome P450 enzyme ( include quinidine , tyramine , ketoconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan , etc . ) know prolong QT interval ( include amiodarone , bepridil chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , quinolones , sotalol , sparfloxacin , thioridazine , ) barbiturates , opiate , phenothiazine . 22 . Use therapeutic agent know alter major organ function ( e.g. , barbiturate , opiate , phenothiazine , cimetidine , etc . ) within 30 day prior dose . 23 . Consumption product contain grapefruit within 10 day prior dose . 24 . Any special dietary change 30 day prior dose , deem Principal Investigator consultation Sponsor Medical Monitor . 25 . Any strenuous exercise within 7 day Checkin , deem Principal Investigator consultation Sponsor Medical Monitor . 26 . Donation whole blood significant loss blood within 56 day prior dose . 27 . Plasma donation within 7 day prior dose . 28 . Participation another interventional clinical trial within 30 day prior dose . Based Lab Abnormalities 29 . Any serum creatinine BUN measure beyond upper limit normal range Screening Checkin . Individual value may discuss Sponsor Medical Monitor . 30 . Hemoglobin &lt; 12.0 g/dL screen visit . 31 . Positive Screening test HCV , HBV , HIV . 32 . Any factor suggest Principal Investigator subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>PA-824 ,</keyword>
	<keyword>midazolam</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pretomanid</keyword>
	<keyword>CL-006</keyword>
</DOC>